RFXANK

RFXANK (RFX-B) is the smallest subunit of the heterotrimeric RFX transcription factor complex that governs MHC class II gene expression, and loss-of-function mutations in it cause the predominant complementation group B of bare lymphocyte syndrome through abolition of MHC class II transcription (PMID:10072068, PMID:21908431). Although it lacks a DNA-binding domain, its three ankyrin repeats serve as a scaffold that simultaneously engages RFXAP and CIITA on opposite faces of the ankyrin repeat domain; RFXAP binding depends on a surface within the ankyrin groove, and patient mutations such as D121V abolish RFX complex assembly by disrupting RFXAP binding (PMID:11463838, PMID:12618906). A separate function maps to the fourth ankyrin repeat: the Y224A mutant assembles an RFX complex that binds the MHC II promoter normally yet fails to transactivate, defining a transactivation step beyond promoter occupancy (PMID:12618906). RFXANK is also a target of negative regulation, as class IIa HDACs (HDAC4 and HDAC5) associate with its ankyrin repeats and with CIITA to repress CIITA-induced MHC II and endogenous HLA-DRA expression, a repression relieved when CaMK phosphorylation drives CRM1-dependent nuclear export of the HDAC/RFXANK complex (PMID:16236793, PMID:15964851). Functionally, RFXANK deficiency in patients eliminates MHC class II surface expression and CD4+ T cell antigen presentation, a defect correctable by hematopoietic stem cell transplantation (PMID:21908431).

1. 1999 High

   Established the molecular identity of the BLS group B gene by purifying RFXANK as the smallest RFX subunit, linking an ankyrin-repeat protein lacking DNA-binding activity to loss of MHC class II transcription.

   Evidence Protein purification, sequencing, and complementation in BLS patient cell lines

   PMID:10072068

   Open questions at the time

   • Did not resolve how a DNA-binding-deficient subunit contributes to promoter function
   • Interaction surfaces with other RFX subunits not yet mapped
2. 2000 Medium

   Defined the genetic basis of group B disease by identifying a North African founder deletion as the major RFXANK lesion abolishing RFX complex assembly.

   Evidence Mutation and haplotype analysis across patients with functional complementation

   PMID:10803838

   Open questions at the time

   • Founder effect is genetic/epidemiological rather than direct biochemical proof of the assembly defect
3. 2000 Medium

   Revealed that RFXANK deficiency is distinct from RFX5/RFXAP loss, since exogenous CIITA can partially restore MHC expression, implicating RFXANK in a CIITA-influenced step.

   Evidence CIITA transfection rescue and MHC reporter assays in patient fibroblasts

   PMID:10725724

   Open questions at the time

   • Mechanism of partial CIITA override not defined
   • Single lab, patient-cell-based readouts
4. 2001 High

   Resolved the architectural role of the ankyrin repeats, showing RFXANK uses opposite faces to bind RFXAP and CIITA simultaneously and that a patient mutation disrupts only the RFXAP-binding groove.

   Evidence Computational modeling, alanine-scanning mutagenesis, in vitro and in vivo binding assays

   PMID:11463838

   Open questions at the time

   • No experimental structure of the assembled complex
   • Stoichiometry on the promoter not determined
5. 2003 High

   Separated RFXANK's assembly function from its transactivation function via two missense mutants, showing D121 is needed for RFXAP binding while Y224 is dispensable for promoter binding but required for transactivation.

   Evidence Site-directed mutagenesis, protein interaction and DNA binding assays, MHC II expression analysis in patient cells

   PMID:12618906

   Open questions at the time

   • The additional protein inferred to bind the fourth ankyrin repeat was not identified
   • Direct transactivation partner remains uncharacterized
6. 2005 High

   Identified RFXANK as a regulatory target by showing class IIa HDAC4/HDAC5 bind its ankyrin repeats and repress CIITA-driven MHC II transcription in a CaMK-phosphorylation/CRM1-export-dependent manner.

   Evidence Yeast two-hybrid, co-immunoprecipitation, interaction mapping, promoter and HLA-DRA expression assays, CaMK/nuclear export assays

   PMID:15964851 PMID:16236793

   Open questions at the time

   • Physiological signals controlling CaMK-driven repression in immune cells not defined
   • Whether HDAC binding competes directly with RFXAP/CIITA on the ankyrin surface not resolved
7. 2011 Medium

   Consolidated RFXANK as the dominant cause of MHC class II deficiency and demonstrated that the resulting immunodeficiency is correctable, confirming RFXANK is essential for immune MHC II expression.

   Evidence Genetic and immunological analysis of 35 patients with HSCT outcome data

   PMID:21908431

   Open questions at the time

   • Clinical/genetic rather than direct biochemical mechanism
   • Does not address tissue-specific roles outside the immune system

• The identity of the protein bound by the fourth ankyrin repeat that mediates RFXANK-dependent transactivation beyond promoter occupancy remains unknown.
• No candidate partner for the transactivation step identified
• No structural model of the RFXANK transactivation interface